Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lovastatin and simvastatin prevention studies.

P H Jones1

  • 1Baylor College of Medicine, Houston, Texas 77030.

The American Journal of Cardiology
|September 18, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precancerous niche remodelling dictates nascent tumour persistence.

Nature·2026
Same author

Modelling red blood cell optical trapping by machine learning improved geometrical optics calculations.

Biomedical optics express·2023
Same author

Influence of slow light effect on trapping force in optical tweezers.

Optics letters·2022
Same author

Mutant clones in normal epithelium outcompete and eliminate emerging tumours.

Nature·2021
Same author

New approaches to pharmacosurveillance for monitoring prescription frequency, diversity, and co-prescription in a large sentinel network of companion animal veterinary practices in the United Kingdom, 2014-2016.

Preventive veterinary medicine·2018
Same author

Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials.

Diabetic medicine : a journal of the British Diabetic Association·2018

New statin drugs like lovastatin and simvastatin effectively lower cholesterol. Planned trials will assess their long-term safety and efficacy in preventing coronary artery disease (CAD) events and improving survival in high-risk patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Drug treatment for hypercholesterolemia significantly reduces coronary artery disease (CAD) events in patients without known CAD.
  • Established drugs like cholestyramine and gemfibrozil have demonstrated efficacy and safety in managing hyperlipidemia.
  • A new class of hypolipidemic agents, statins (e.g., lovastatin, simvastatin), show exceptional efficacy in lowering cholesterol.

Purpose of the Study:

  • To evaluate the potential of lovastatin and simvastatin as first-line treatments for high-risk hypercholesterolemia.
  • To assess the impact of long-term statin therapy on reducing fatal and nonfatal CAD events.
  • To determine if statin treatment improves overall survival in patients with ischemic heart disease and hypercholesterolemia.

Main Methods:

Related Experiment Videos

  • A US-based double-blind, placebo-controlled trial involving 8,000 patients without CAD to assess lovastatin's effect on CAD events over 5 years.
  • A Scandinavian study of 4,000 patients with ischemic heart disease to evaluate simvastatin's impact on survival and cardiac events over 3 years.
  • Comparison of these study designs with existing research and presentation of expected impacts on CAD event rates.

Main Results:

  • Statins, including lovastatin and simvastatin, competitively inhibit HMG-CoA reductase, a key enzyme in cholesterol synthesis.
  • Safety and efficacy studies suggest statins are valuable for high-risk hypercholesterolemic patients.
  • Long-term clinical trials are planned to confirm these findings in large patient cohorts.

Conclusions:

  • Lovastatin and simvastatin represent a promising new class of hypolipidemic agents.
  • Planned trials are crucial for establishing statins as effective first-line therapies for preventing CAD events.
  • The expected outcomes of these trials will significantly influence future management strategies for hypercholesterolemia and CAD prevention.